AdCAR-T Development Service for Antigen Re-Targeting

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides an advanced AdCAR-T Development Service for Antigen Re-Targeting, designed to address key challenges such as antigen escape, tumor heterogeneity, and on-target/off-tumor toxicity. By utilizing an innovative modular split-component receptor design, our platform enables precise and flexible multi-antigen targeting, significantly improving safety and therapeutic efficacy. This next-generation solution empowers researchers to overcome antigen–loss–driven relapse and accelerate the development of adaptable CAR-T therapies for solid tumors.

Introduction

Adapter CAR-T (AdCAR-T) technology addresses the fundamental limitations of single-specificity CARs by employing a split recognition/activation design. This system engineers T cells to recognize a universal label rather than a tumor antigen. A separate, non-engineered adapter molecule (AM) acts as the bridge, binding the tumor antigen and the AdCAR-T cell simultaneously.

Diagram of a Generic CAR Structure. (OA Literature) Fig.1 Schematic of an adaptor CAR structure.¹

Creative Biolabs' AdCAR-T Development Service

The core value of our AdCAR-T system is its flexibility and control. Unlike conventional, fixed-target CARs, our platform separates T-cell activation from antigen recognition. This allows a single, universally engineered T-cell product to be redirected against any target simply by changing the external AM.

We provide a direct solution to the two biggest challenges in cell therapy:

Solving Antigen Escape: We enable the sequential or simultaneous targeting of multiple tumor antigens without needing to re-engineer the T cell. If a tumor loses Target A, you simply switch or add an AM for Target B, maintaining therapeutic pressure and preventing relapse.
Mitigating Toxicity: The therapeutic activity is strictly dependent on the presence and dosage of the AM. This provides a crucial, externally controlled "off-switch" functionality, allowing clinicians to immediately withdraw the AM to manage severe side effects.
Precision Targeting: We facilitate the development of differential lysis strategies, where T-cell activation is tuned to only occur when cancer cells exhibit specific antigen expression profiles, dramatically improving the therapeutic window against targets shared by healthy tissues.

Discover How We Can Help – Request a Consultation to discuss your specific antigen targets and program goals.

What We Can Offer

AdCAR-T cells employ a universal CAR structure that binds to a customizable adaptor molecule. This adaptor molecule bridges the CAR-T cell and the tumor cell, carrying both an antigen-specific antibody fragment and a tag recognized by the AdCAR.

Receptor & Adaptor Architecture Universal CAR receptor design Adaptor molecule engineering	Modular antigen-switching capability The ability to swap adaptors to target different antigens without re-engineering the CAR T cell itself.
Activity control / safety "switch" mechanisms Engineering control features (e.g., OFF‐switch adaptors, dose dependence, conditional triggers) to modulate CAR T cell activation and reduce toxicity.	Multiplex / multi-antigen targeting & heterogeneity coverage Leveraging adaptor combinations or universal CARs to target tumor antigen heterogeneity and escape.

Comprehensive Development Workflow

To initiate an AdCAR-T development project, clients typically need to provide target antigen information for 2-3 Tumor-Associated Antigens (TAAs), the sequence for the adapter molecule, and a source of T-cells for engineering and validation.

Workflow of AdCAR-T Development. (Creative Biolabs Original)

The final project deliverables consist of three primary components: a comprehensive AdCAR vector report, a validated AdCAR-T cell line with a complete data package, and a detailed adpter molecule specification report.

Advantages

Rapid antigen switching without re-engineering CAR-T cells.
Adjustable activity via adaptor dosing for enhanced safety.
Effective strategy against antigen escape and tumor heterogeneity.
Broad compatibility with multiple antibody or fusion protein formats.

FAQs

How does AdCAR-T compare to bispecific or tandem CARs?

Unlike fixed bispecific or tandem CARs, AdCAR-T is dynamically re-targetable by switching the AM, enabling immediate adaptation to antigen escape without re-engineering the T cells.

What is the key safety advantage of AdCAR-T?

Activity is controlled by AM dosage. Stopping AM infusion acts as a rapid "off-switch", offering reversible control to manage severe toxicities.

Can I use my proprietary antibodies as AMs?

Yes. We conjugate and characterize your proprietary antibodies or fragments into validated Adapter Molecules, integrating them seamlessly into our platform.

What is the expected persistence of AdCAR-T cells?

AdCAR-T cells are built on persistent backbones and remain resting without constant stimulation, supporting long-term readiness and reduced exhaustion.

Partner with Us

Creative Biolabs delivers the next-generation solution to cell therapy's greatest challenges with the AdCAR-T Development Service for Antigen Re-Targeting. We provide the missing link: a platform that guarantees controllable activity, multiplexed efficacy, and superior safety for your novel oncology program. To begin the conversation about integrating our modular cell therapy platform into your pipeline, please reach out to our scientific strategy team.

Reference

Liu, Delong et al. "Engineering switchable and programmable universal CARs for CAR T therapy." Journal of hematology & oncology vol. 12,1 69. 4 Jul. 2019. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s13045-019-0763-0

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.